Video

Dr. Damon on Optimal Treatment Regimens in AYA ALL

Author(s):

Lloyd Damon, MD, discusses optimal treatment regimens in adolescent/young adult acute lymphoblastic leukemia.

Lloyd Damon, MD, clinical professor, Department of Medicine, University of California, San Francisco (UCSF), director, Hematologic Malignancies and Bone Marrow Transplant, UCSF Robert O. and Angela W. Johnson Endowed Chair in Hematologic Malignancies, UCSF Helen Diller Family Comprehensive Cancer Center, discusses optimal treatment regimens in adolescent/young adult (AYA) acute lymphoblastic leukemia (ALL) .

AYA ALL was initially defined as patients aged 16 to 21 as these patients had suboptimal 5-year survival rates compared with younger patients and adult patients, says Damon. Now, patients aged 15 to 29 years are considered AYA. Historically, these patients were treated with adult regimens rather than pediatric-inspired regimens, which may have contributed to their poor survival, adds Damon.

Pediatric-inspired regimens are modeled on the Berlin-Frankfurt-Munich regimen, which consists of a myelosuppressive induction treatment, 2 lymphocytotoxic consolidation treatments, followed by myelosuppressive intensification and maintenance therapy. Data from the CALGB 10403 trial showed that a pediatric-inspired regimen was safe and feasible in AYA patients, concludes Damon.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity